Once-weekly exenatide uses a proprietary technology for long-acting medications developed by Alkermes. The technology encapsulates active medication into polymer-based microspheres that are injected into the body where they degrade slowly, gradually releasing the drug at a carefully controlled rate.
The 30-week, open-label, noninferiority study included 295 subjects with type 2 diabetes who were not achieving adequate glucose control using diet and exercise with or without the use of one or more oral antidiabetic agents. Subjects were randomized to receive subcutaneous injections of either once- weekly exenatide 2.0 milligrams or BYETTA taken twice daily as outlined in the approved label. Subjects in both groups who completed the randomized portion of the study continued in the open-ended portion of the study receiving once- weekly exenatide.
Full study results will be included in future scientific publications.
Webcast Investor Conference Call
Amylin Pharmaceuticals will webcast a conference call to discuss these study results today, Wednesday, October 31 at 8:30 a.m. ET (5:30 a.m. PT). Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will lead the call.
The call will be webcast live through Amylin's corporate website and a
recording will be made available following the close of the call. To access
the webcast, please log on to http://www.amylin.com approximately fifteen minutes
prior to the call to register, download and install any necessary audio
software. For those without access to the Internet, the live call may be
accessed by phone by calling (866) 356-3095 (domestic) or (617) 597-5391
(international), passcode 19644079. A replay of the ca
|SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved